SOURCE: Deinove

February 10, 2010 02:51 ET

Deinove selected to present at CleanEquity Monaco 2010

PARIS--(Marketwire - February 10, 2010) - Deinove, a biotech company dedicated to the research and development of innovative processes for biofuel production, has been selected to present at CleanEquity Monaco 2010, the foremost event for next generation clean and green technology. The conference will take place on March 4th and 5th at the Sporting d'Hiver in Monaco.

Jacques Biton, CEO of Deinove, will be presenting on Thursday March, 4th to invited industry-specific financial and strategic investors, policy makers, legislators and media.

Innovator Capital, London specialist investment bank, hosts the annual invitation-only event. CleanEquity Monaco's regional host is the Monaco Chamber of Economic Development. Other local partners include Prince Albert II of Monaco's Foundation, the Monte Carlo SBM, and the Stelios Philanthropic Foundation. Collaborators for the 2010 event include Arup, Covington and Burling LLP, the Hugin Group, Invest Securities, Royal Philips Electronics NV and the UNEP Fi.

"Deinove is pleased to present its recent development and corporate strategy at the world-renowned CleanEquity Monaco 2010. This would be a great opportunity for us to present our breakthrough industrial microbial processes for the production of 2nd-generation biofuels, chemical commodities and compounds of industrial interest using Deinococcus and other radio-resistant bacteria", emphasized Deinove CEO Jacques Biton.

About Deinove

Deinove was incorporated in late 2006 under the joint impetus of Philippe Pouletty MD (Managing Partner at the private equity firm Truffle Capital) and Miroslav Radman PhD (Professor of Cell Biology at Paris-Descartes University, a member of the French Academy of Science and winner of the 2003 INSERM Prize for Medical Research). Professor Radman elucidated and patented the genetic mechanism behind the extraordinary biodiversity and robustness of the bacterium Deinococcus, on which Deinove's innovative strategy is based.

Deinove is dedicated to the development and commercial exploitation of innovative technological processes for the production of biofuels and other compounds of industrial or pharmaceutical interest by exploiting the Deinococci's exceptional natural properties. Deinove intends to leverage its proprietary bacteria, technologies and processes by outlicensing to industrial partners.

Deinove has forged several strong collaborations with leading academic laboratories at Paris-Descartes University (Miroslav Radman and Ivan Matic), IGS-CNRS Marseille (Jean-Michel Claverie), CPBS CNRS-University of Montpellier (Jean-Paul Leonetti) and INSA Toulouse (Carole Jouve and Gérard Goma).

To date, Deinove has received a total of EUR 3.4 million in equity investment from Truffle Capital and received EUR 8.9 million in funding (including EUR 6 million for Deinove) from the French government's Strategic Industrial Innovation programme. The other project partners are Tereos (Europe's leading bioethanol producer), its BENP Lillebonne and Syral subsidiaries and two academic labs. The DEINOL project's goal is to pioneer ways of producing lignocellulosic ("second-generation") ethanol in existing industrial installations and without the need for massive additional investment.

Deinove currently employs 14 staff. The company is headquartered in Paris and operates laboratory facilities at the Cap Alpha technology park in Montpellier, as part of its collaborative work with expert academic labs.

This information is provided by HUGIN

Contact Information

  • Press contacts

    Caroline Carmagnol
    Tel.: +33 (0)6 64 18 99 59
    Email Contact

    Charles Catherinot
    Tel.: +33 (0)1 42 68 86 40
    Email Contact

    Juliette Vandenbroucque
    Tel.: +33 (0)1 42 68 86 40
    Email Contact

    Angelita de Francisco
    Business Development
    Tel.: +33 (0)6 07 15 28 87
    Email Contact